Market closedADR

BioLineRx/$BLRX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About BioLineRx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Ticker

$BLRX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Hevel Modi'in, Israel

Employees

Website

www.biolinerx.com

BioLineRx Metrics

BasicAdvanced

$15M

-

-$0.02

1.01 -

Price and volume

Market cap

$15M

Beta

1.01

52-week high

$1.44

52-week low

$0.13

Average daily volume

7.7M

Financial strength

Current ratio

1.516

Quick ratio

1.327

Long term debt to equity

226.631

Total debt to equity

348.195

Interest coverage (TTM)

-7.56%

Management effectiveness

Return on assets (TTM)

-32.96%

Return on equity (TTM)

-184.09%

Valuation

Price to revenue (TTM)

7.127

Price to book

6.49

Price to tangible book (TTM)

-11.64

Price to free cash flow (TTM)

-5.164

Growth

Earnings per share change (TTM)

-69.22%

3-year earnings per share growth (CAGR)

-34.30%

What the Analysts think about BioLineRx

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BioLineRx stock.

BioLineRx Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

BioLineRx Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BioLineRx News

AllArticlesVideos

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Benzinga·1 week ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BLRX

$

Capital at risk

Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioLineRx stock?

BioLineRx (BLRX) has a market cap of $15M as of January 15, 2025.

What is the P/E ratio for BioLineRx stock?

The price to earnings (P/E) ratio for BioLineRx (BLRX) stock is 0 as of January 15, 2025.

Does BioLineRx stock pay dividends?

No, BioLineRx (BLRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next BioLineRx dividend payment date?

BioLineRx (BLRX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioLineRx?

BioLineRx (BLRX) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.